Aurinia Pharmaceuticals Inc (AUPH) Expected to Announce Earnings of -$0.14 Per Share

Analysts expect that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will post earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks. Four analysts have provided estimates for Aurinia Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.19). Aurinia Pharmaceuticals reported earnings of ($0.22) per share during the same quarter last year, which suggests a positive year over year growth rate of 36.4%. The business is expected to report its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full-year earnings of ($1.08) per share for the current financial year, with EPS estimates ranging from ($1.19) to ($1.02). For the next financial year, analysts expect that the company will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.87) to ($0.52). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. Aurinia Pharmaceuticals’s revenue for the quarter was up .0% compared to the same quarter last year.

AUPH has been the subject of several recent research reports. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. BidaskClub raised Aurinia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a research note on Monday, October 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $10.79.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its stake in Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the period. Wells Fargo & Company MN grew its stake in Aurinia Pharmaceuticals by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 26,395 shares during the period. Cutler Capital Management LLC grew its stake in Aurinia Pharmaceuticals by 33.3% during the third quarter. Cutler Capital Management LLC now owns 40,000 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 10,000 shares during the period. Investment Centers of America Inc. grew its stake in Aurinia Pharmaceuticals by 100.0% during the third quarter. Investment Centers of America Inc. now owns 60,000 shares of the biotechnology company’s stock worth $376,000 after purchasing an additional 30,000 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in Aurinia Pharmaceuticals by 1.1% in the second quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock valued at $502,000 after acquiring an additional 931 shares during the period. 28.08% of the stock is owned by institutional investors and hedge funds.

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) opened at $5.18 on Friday. The firm has a market capitalization of $445.06, a PE ratio of -4.28 and a beta of 2.34. Aurinia Pharmaceuticals has a one year low of $2.95 and a one year high of $10.54.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/02/aurinia-pharmaceuticals-inc-auph-expected-to-announce-earnings-of-0-14-per-share.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply